These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18757503)

  • 41. A novel biological role for the phospholipid lysophosphatidylinositol in nociceptive sensitization via activation of diverse G-protein signalling pathways in sensory nerves in vivo.
    Gangadharan V; Selvaraj D; Kurejova M; Njoo C; Gritsch S; Škoricová D; Horstmann H; Offermanns S; Brown AJ; Kuner T; Tappe-Theodor A; Kuner R
    Pain; 2013 Dec; 154(12):2801-2812. PubMed ID: 23973358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.
    Ross RA
    Trends Pharmacol Sci; 2011 May; 32(5):265-9. PubMed ID: 21367464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is the natural ligand of GPR55?
    Okuno T; Yokomizo T
    J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is GPR55 an anandamide receptor?
    Brown AJ; Robin Hiley C
    Vitam Horm; 2009; 81():111-37. PubMed ID: 19647110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
    Anavi-Goffer S; Irving AJ; Ross RA
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55.
    Kargl J; Balenga NA; Platzer W; Martini L; Whistler JL; Waldhoer M
    Br J Pharmacol; 2012 Apr; 165(8):2611-9. PubMed ID: 21718301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling.
    Stam JC; Michiels F; van der Kammen RA; Moolenaar WH; Collard JG
    EMBO J; 1998 Jul; 17(14):4066-74. PubMed ID: 9670021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55.
    Balenga NA; Henstridge CM; Kargl J; Waldhoer M
    Adv Pharmacol; 2011; 62():251-77. PubMed ID: 21907912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential changes in GPR55 during microglial cell activation.
    Pietr M; Kozela E; Levy R; Rimmerman N; Lin YH; Stella N; Vogel Z; Juknat A
    FEBS Lett; 2009 Jun; 583(12):2071-6. PubMed ID: 19464294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The enigmatic pharmacology of GPR55.
    Ross RA
    Trends Pharmacol Sci; 2009 Mar; 30(3):156-63. PubMed ID: 19233486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.
    Bartolomé RA; Wright N; Molina-Ortiz I; Sánchez-Luque FJ; Teixidó J
    Cancer Res; 2008 Oct; 68(20):8221-30. PubMed ID: 18922893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
    Zhao P; Abood ME
    Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.
    Kargl J; Balenga N; Parzmair GP; Brown AJ; Heinemann A; Waldhoer M
    J Biol Chem; 2012 Dec; 287(53):44234-48. PubMed ID: 23161546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of PI3K/Akt/GSK3β signaling cascade through G protein-coupled receptor 55 (GPR55) activation: Prenatal lysophosphatidylinositol attenuates valproic acid-induced synaptic abnormalities and mitochondrial dysfunction.
    Ahmed S; Abir AH; Sharmin O; Khurshid N; Akter A; Nakshy NT; Hasan MM; Yesmine S; Rahman M
    Life Sci; 2023 Dec; 334():122195. PubMed ID: 37866808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of calcium signals provoked by lysophosphatidylinositol in human microvascular endothelial cells.
    Al Suleimani YM; Hiley CR
    Physiol Res; 2016; 65(1):53-62. PubMed ID: 26596318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity.
    Moreno-Navarrete JM; Catalán V; Whyte L; Díaz-Arteaga A; Vázquez-Martínez R; Rotellar F; Guzmán R; Gómez-Ambrosi J; Pulido MR; Russell WR; Imbernón M; Ross RA; Malagón MM; Dieguez C; Fernández-Real JM; Frühbeck G; Nogueiras R
    Diabetes; 2012 Feb; 61(2):281-91. PubMed ID: 22179809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.
    Zhou XL; Guo X; Song YP; Zhu CY; Zou W
    Acta Pharmacol Sin; 2018 Mar; 39(3):459-471. PubMed ID: 29188802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray.
    Deliu E; Sperow M; Console-Bram L; Carter RL; Tilley DG; Kalamarides DJ; Kirby LG; Brailoiu GC; Brailoiu E; Benamar K; Abood ME
    Mol Pharmacol; 2015 Aug; 88(2):265-72. PubMed ID: 25972448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55.
    Kotsikorou E; Lynch DL; Abood ME; Reggio PH
    Chem Phys Lipids; 2011 Feb; 164(2):131-43. PubMed ID: 21185816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.
    Morales P; Whyte LS; Chicharro R; Gómez-Cañas M; Pazos MR; Goya P; Irving AJ; Fernández-Ruiz J; Ross RA; Jagerovic N
    J Med Chem; 2016 Mar; 59(5):1840-53. PubMed ID: 26789378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.